Precision BioSciences
Organisation
Trials
Phase 1, Terminated, 48 people, 21 Nov 2019
Phase 1/2, Completed, 18 people, 23 Jul 2019
Named in competing interests
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
Board or leadership role, 25 Jun 2024
Sources: pubmed.ncbi.nlm.nih.gov